Judgment opens way for stem-cell patents

Lawyers describe EU court ruling as boost for medical research

BTG May 2006.Dr Louise Makin

BTG’s Makin transforms fast-growing group

UK healthcare company focuses on buying in specialist treatments

A woman uses a Philips radiology machine

Philips to buy US medical devices group

Dutch company bulks up healthcare business ahead of split

New ways of attacking cancer cells are being developed

Juno IPO highlights latest buzz in US biotech

Cell therapy specialist poised for listing as sector draws investors

Cancer trial successes fuel investment

Adaptimmune flags potential to treat broad range of tumours

The Cancer Drugs Fund is a costly mistake

Labour compounds error in backing treatment with marginal benefit

Bayer fails to block cheap Indian drug

Indian Supreme Court rejects German pharma group’s appeal

Merck’s Ebola vaccine trial suspended

Setback as US nurse is latest to be exposed to virus

Drug resistance to cost $100tn by 2050

UK review urges global action to tackle threat

Surgeons turn to 3D and nanorobots to enhance human judgment and skill

Operating procedures are being transformed

Signs of a revival in drug development

US approvals of new medicines show significant increase

Systems grapple with information deluge

How to harness resources to patients’ advantage is one of the sector’s big challenges

India in frontline in battle over IP rights

Rulings on patents emerge as a significant source of friction between New Delhi and the US

Patients to play active role in digital future

The contours of a more efficient health landscape are slowly coming into view

McLaren aids GSK with racetrack expertise

F1 telemetry is being adapted to monitor patients

The electrical could replace the traditional

Body’s inner language may be key to range of treatment

Mylan pays $50m bonuses to cut tax bill

Awards designed to offset charges resulting from $5.3bn takeover of Abbott unit

Merck/Cubist: pony up

Bet on the right pharma horse, in the right race

Superbug threat drives $9.5bn Merck deal

Cubist purchase shows fresh interest in antibiotics to fight life-threatening infections

Merck to pay $9.5bn for US group Cubist

Massachusetts-based company at forefront of ‘superbugs’ fight


More FT Twitter accounts